Cargando…
SAT611 Prevalence Of Comorbidities Among Treated And Untreated Adults With Suspected Growth Hormone Deficiency
Disclosure: A.R. Hoffman: Consulting Fee; Self; Ascendis. S. Raveendran: Employee; Self; Ascendis Pharma. J. Manjelievskaia: Employee; Self; Veradigm. Research Investigator; Self; Veradigm. A. Komirenko: Employee; Self; Ascendis Pharma. M. Bonafede: Employee; Self; Veradigm. Research Investigator; S...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553983/ http://dx.doi.org/10.1210/jendso/bvad114.1344 |
_version_ | 1785116304044195840 |
---|---|
author | Hoffman, Andrew R Raveendran, Subhara Manjelievskaia, Janna Komirenko, Allison Bonafede, Machaon Winer, Isabelle Cheng, Jennifer Miner, Paul Smith, Alden Raymond |
author_facet | Hoffman, Andrew R Raveendran, Subhara Manjelievskaia, Janna Komirenko, Allison Bonafede, Machaon Winer, Isabelle Cheng, Jennifer Miner, Paul Smith, Alden Raymond |
author_sort | Hoffman, Andrew R |
collection | PubMed |
description | Disclosure: A.R. Hoffman: Consulting Fee; Self; Ascendis. S. Raveendran: Employee; Self; Ascendis Pharma. J. Manjelievskaia: Employee; Self; Veradigm. Research Investigator; Self; Veradigm. A. Komirenko: Employee; Self; Ascendis Pharma. M. Bonafede: Employee; Self; Veradigm. Research Investigator; Self; Veradigm. Stock Owner; Self; Veradigm. I. Winer: Employee; Self; Veradigm. Research Investigator; Self; Veradigm. J. Cheng: Employee; Self; Veradigm. Research Investigator; Self; Veradigm. P. Miner: Employee; Self; Ascendis Pharma. A.R. Smith: Employee; Self; Ascendis Pharma. Introduction: Adult growth hormone deficiency (AGHD) is associated with an increased risk of morbidity and mortality, yet is known to be underdiagnosed and undertreated. Untreated or undertreated patients with AGHD can experience reduced quality of life, adverse changes in metabolic and cardiovascular (CV) function, and increased risk of other comorbidities. This study captured and described suspected AGHD cases based on a previously published algorithm in order to characterize the treatment rate and clinical burden of this disease. Methods: Using the Veradigm Network EHR database linked to administrative claims, this retrospective cohort study selected adult patients with suspected AGHD between 1/1/2017 and 12/31/2021 based on: hypopituitarism diagnosis or ≥1 diagnosis for related conditions, ≥3 pituitary hormone deficiencies, ≥3 replacement therapies with pituitary hormones or vasopressin, or ≥1 prescription for GH. Index date was based on the earliest qualifying event. Baseline demographics and clinical characteristics were assessed throughout the 12-month baseline period. Receipt of GH treatment was assessed throughout the 12-month baseline and 12-month follow-up periods. Results: Of the 51,588 patients with suspected AGHD, 59% were female, median age was 51 years, and 59% were White. About 3.2% had evidence of GH therapy during the study period. Among the 1,659 GH-treated patients, 40% were treated during both baseline and follow-up. Median age among treated patients was 48 years and 53% were male. At baseline, the top clinical comorbidities among the overall cohort were CV disease (52%), hyperlipidemia (47%), endocrine-related conditions (45%), mental health conditions (43%), and sleep disorders (29%). Treated adults had higher proportions of endocrine-related conditions (66% vs 44%), the most prevalent of which were hypopituitarism (38% vs 6%), hypothyroidism (37% vs 29%), and hypogonadism (27% vs 17%) compared to untreated. Higher proportions of CV disease (52% vs 36%), hyperlipidemia (47% vs 36%), obesity (35% vs 20%), diabetes mellitus (27% vs 15%), and liver disease (14% vs 11%) were observed in the untreated vs treated cohort. Prevalence of depression, anxiety, and sleep disorders was observed in about a third of both cohorts (treated and untreated). Conclusions: Most adults with suspected GHD remain untreated. Fewer than 4% of suspected AGHD patients in our study were treated with GH. Substantially higher proportions of clinical conditions related to metabolic and CV function were observed among the untreated cohort supporting the need for improved diagnosis and management of this disease. Presentation: Saturday, June 17, 2023 |
format | Online Article Text |
id | pubmed-10553983 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-105539832023-10-06 SAT611 Prevalence Of Comorbidities Among Treated And Untreated Adults With Suspected Growth Hormone Deficiency Hoffman, Andrew R Raveendran, Subhara Manjelievskaia, Janna Komirenko, Allison Bonafede, Machaon Winer, Isabelle Cheng, Jennifer Miner, Paul Smith, Alden Raymond J Endocr Soc Neuroendocrinology And Pituitary Disclosure: A.R. Hoffman: Consulting Fee; Self; Ascendis. S. Raveendran: Employee; Self; Ascendis Pharma. J. Manjelievskaia: Employee; Self; Veradigm. Research Investigator; Self; Veradigm. A. Komirenko: Employee; Self; Ascendis Pharma. M. Bonafede: Employee; Self; Veradigm. Research Investigator; Self; Veradigm. Stock Owner; Self; Veradigm. I. Winer: Employee; Self; Veradigm. Research Investigator; Self; Veradigm. J. Cheng: Employee; Self; Veradigm. Research Investigator; Self; Veradigm. P. Miner: Employee; Self; Ascendis Pharma. A.R. Smith: Employee; Self; Ascendis Pharma. Introduction: Adult growth hormone deficiency (AGHD) is associated with an increased risk of morbidity and mortality, yet is known to be underdiagnosed and undertreated. Untreated or undertreated patients with AGHD can experience reduced quality of life, adverse changes in metabolic and cardiovascular (CV) function, and increased risk of other comorbidities. This study captured and described suspected AGHD cases based on a previously published algorithm in order to characterize the treatment rate and clinical burden of this disease. Methods: Using the Veradigm Network EHR database linked to administrative claims, this retrospective cohort study selected adult patients with suspected AGHD between 1/1/2017 and 12/31/2021 based on: hypopituitarism diagnosis or ≥1 diagnosis for related conditions, ≥3 pituitary hormone deficiencies, ≥3 replacement therapies with pituitary hormones or vasopressin, or ≥1 prescription for GH. Index date was based on the earliest qualifying event. Baseline demographics and clinical characteristics were assessed throughout the 12-month baseline period. Receipt of GH treatment was assessed throughout the 12-month baseline and 12-month follow-up periods. Results: Of the 51,588 patients with suspected AGHD, 59% were female, median age was 51 years, and 59% were White. About 3.2% had evidence of GH therapy during the study period. Among the 1,659 GH-treated patients, 40% were treated during both baseline and follow-up. Median age among treated patients was 48 years and 53% were male. At baseline, the top clinical comorbidities among the overall cohort were CV disease (52%), hyperlipidemia (47%), endocrine-related conditions (45%), mental health conditions (43%), and sleep disorders (29%). Treated adults had higher proportions of endocrine-related conditions (66% vs 44%), the most prevalent of which were hypopituitarism (38% vs 6%), hypothyroidism (37% vs 29%), and hypogonadism (27% vs 17%) compared to untreated. Higher proportions of CV disease (52% vs 36%), hyperlipidemia (47% vs 36%), obesity (35% vs 20%), diabetes mellitus (27% vs 15%), and liver disease (14% vs 11%) were observed in the untreated vs treated cohort. Prevalence of depression, anxiety, and sleep disorders was observed in about a third of both cohorts (treated and untreated). Conclusions: Most adults with suspected GHD remain untreated. Fewer than 4% of suspected AGHD patients in our study were treated with GH. Substantially higher proportions of clinical conditions related to metabolic and CV function were observed among the untreated cohort supporting the need for improved diagnosis and management of this disease. Presentation: Saturday, June 17, 2023 Oxford University Press 2023-10-05 /pmc/articles/PMC10553983/ http://dx.doi.org/10.1210/jendso/bvad114.1344 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Neuroendocrinology And Pituitary Hoffman, Andrew R Raveendran, Subhara Manjelievskaia, Janna Komirenko, Allison Bonafede, Machaon Winer, Isabelle Cheng, Jennifer Miner, Paul Smith, Alden Raymond SAT611 Prevalence Of Comorbidities Among Treated And Untreated Adults With Suspected Growth Hormone Deficiency |
title | SAT611 Prevalence Of Comorbidities Among Treated And Untreated Adults With Suspected Growth Hormone Deficiency |
title_full | SAT611 Prevalence Of Comorbidities Among Treated And Untreated Adults With Suspected Growth Hormone Deficiency |
title_fullStr | SAT611 Prevalence Of Comorbidities Among Treated And Untreated Adults With Suspected Growth Hormone Deficiency |
title_full_unstemmed | SAT611 Prevalence Of Comorbidities Among Treated And Untreated Adults With Suspected Growth Hormone Deficiency |
title_short | SAT611 Prevalence Of Comorbidities Among Treated And Untreated Adults With Suspected Growth Hormone Deficiency |
title_sort | sat611 prevalence of comorbidities among treated and untreated adults with suspected growth hormone deficiency |
topic | Neuroendocrinology And Pituitary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553983/ http://dx.doi.org/10.1210/jendso/bvad114.1344 |
work_keys_str_mv | AT hoffmanandrewr sat611prevalenceofcomorbiditiesamongtreatedanduntreatedadultswithsuspectedgrowthhormonedeficiency AT raveendransubhara sat611prevalenceofcomorbiditiesamongtreatedanduntreatedadultswithsuspectedgrowthhormonedeficiency AT manjelievskaiajanna sat611prevalenceofcomorbiditiesamongtreatedanduntreatedadultswithsuspectedgrowthhormonedeficiency AT komirenkoallison sat611prevalenceofcomorbiditiesamongtreatedanduntreatedadultswithsuspectedgrowthhormonedeficiency AT bonafedemachaon sat611prevalenceofcomorbiditiesamongtreatedanduntreatedadultswithsuspectedgrowthhormonedeficiency AT winerisabelle sat611prevalenceofcomorbiditiesamongtreatedanduntreatedadultswithsuspectedgrowthhormonedeficiency AT chengjennifer sat611prevalenceofcomorbiditiesamongtreatedanduntreatedadultswithsuspectedgrowthhormonedeficiency AT minerpaul sat611prevalenceofcomorbiditiesamongtreatedanduntreatedadultswithsuspectedgrowthhormonedeficiency AT smithaldenraymond sat611prevalenceofcomorbiditiesamongtreatedanduntreatedadultswithsuspectedgrowthhormonedeficiency |